What is the price forecast for Selumetinib in 2025?

Selumetinib (Selumetinib) is the world's first MEK inhibitor approved for the treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromatosis . Since its launch, its price has been relatively high due to its precise efficacy and scarcity.

According to domestic drug information, the original drug selumetinib has been officially launched in China and included in the medical insurance catalog. This policy has greatly reduced the financial burden on patients. At present, common domestic specifications include 10 mg 60 capsules and 25 mg 60 capsules. One box is priced at about RMB 20,000. After medical insurance reimbursement, the patient's out-of-pocket payment ratio has dropped significantly, and the actual expenditure cost has been significantly reduced compared to the initial stage of the market.

From the overseas market, the price of the European version of the original version of selumetinib is more expensive.The price of 10 mg*60 tablets is about RMB 50,000 or more, which fluctuates greatly due to exchange rates and import channels. As demand for the drug continues to rise globally, supply in some regions will also cause price fluctuations in the short term. In recent years, generic drugs have been launched in some countries and regions. For example, the generic version of selumetinib with the same specifications launched by Lucius Pharmaceuticals in Laos is priced at approximately RMB 1,000 to 2,000 per box. Although the cost is lower, the drug ingredients, dosage and bioequivalence must be strictly verified. For patients, they should follow the doctor's guidance when choosing drugs to ensure that the drugs are from regular sources and of reliable quality.

Generally speaking, as an important targeted drug in the dual fields of rare diseases and tumors, the price of selumetinib is affected by multiple factors such as R&D costs, production processes, and market scarcity. However, with the development of the global generic drug industry and the optimization of medical insurance policies, its accessibility will be further improved, making this innovative treatment affordable for more patients.

Reference materials:https://www.koselugo.com